Strong growth masked by cost pressure, TICMPL execution risk
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Prior guidance (double-digit growth, margin recovery) intact; FY27 EV breakeven targets on track but volume/cost misses narrowing margin of safety.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
TI delivered strong consolidated revenue growth (33% YoY) and PAT growth (39%), with core segments healthy. However, near-term margin recovery is uncertain—commodity and FX headwinds are acute, and TICMPL (high-capex EV venture) volumes are below management's own comfort level, with profitability still 2-4 quarters away. Stock down 50% from Oct 2024 suggests market skepticism on capital efficiency.
₹7330.3 Cr
Revenue · +32.7% YoY₹420.6 Cr
Reported PAT · +39.2% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Double-digit growth trajectory at consolidated level
MET32.7% YoY revenue growth, 39.2% PAT growth
Medical business growing 20% YoY with profitability
METConfirmed on call; exact Q2 contribution not itemized separately
Cost headwinds will be recovered in next 1-2 quarters
OVERSTATEDQ2 margins compressed (10% OPM vs prior guidance); recovery timing unverified
TICMPL volumes scaling across four businesses
MISSQ2: Truck 311, 3W 2,242, SCV 483, Tractor 50 units; analyst noted 'not happy, should be higher'
TICMPL HCV will be EBITDA breakeven Q4 FY27
UnverifiedBreakeven target stated; not yet achieved; costs 75% above run-rate
Earnings quality
What changed since the last call
Cost pressure intensity
DowngradeCommodity and FX headwinds more acute than prior call implied; recovery pushed to 1-2 quarters vs immediate (i.e., delay in margin normalization).
TICMPL capital requirement
NeutralRs 250 Cr Q3 investment confirmed; total Rs 600-700 Cr annual group capex plan reaffirmed (no change).
EV breakeven timeline
NeutralHCV Q4 FY27, two others Q4 FY28 reaffirmed; no movement vs prior call.
The Q&A
Analysts pressed hard on TICMPL volumes (Vipulkumar: 'should be higher'), profitability lag (Salil Desai: costs 75% above run-rate), and capital allocation (Gnanasundaram: why accumulate cash?). Management held confident but hedged on price increases ('market may not be ready') and blamed external factors (commodity, FX). Credibility strained by acknowledgment of miss.
TICMPL volume scaling — Vipulkumar Shah, Sumangal Investments
AnsweredI am not happy with any of the four numbers. All four should be higher. Competition intensifying but we have 25-26% market share in two, targeting leadership.
TICMPL profitability gap — Salil Desai, Marcellus Investment Managers
PartialCommodity costs, cell prices, rupee weakness drove BOM cost increase. We will take price hikes, reduce costs via BOM optimization, and improve deal realization. Timeline uncertain.
Operating margin stagnation — Gopalakrishnan S, Uthrasuuli Investment
DodgedT1, T2, T3 strategy: core business focus, new initiatives, selective acquisitions. Will achieve double-digit growth and higher margins. TICMPL is a major opportunity. Profitability a matter of time and confidence.
TICMPL breakeven credibility — Rushabh Shah, RBSA Investment Managers
PartialFour businesses at different maturity stages. Scale, BOM cost focus, after-sales support, and new use cases will drive profitability. Two-three tailwinds under way. Timeframe firm but execution-dependent.
Medical profitability — Anupam Gupta, HDFC MF
PartialWill take time to stabilize. Our perspective is higher double-digit teen numbers. Once investments settle and team in place (by Q3), profitability will improve significantly.
Core business capex and cash flow — Gnanasundaram S, Avendus Park
AnsweredTICMPL, medical, CDMO are major investments internally funded. Will deploy cash opportunistically into new ventures if right opportunity appears. Not holding excess; working on capital allocation principles.
International business headroom — Gnanasundaram S, Avendus Park
AnsweredGeopolitical issues prevented growth. Now stabilized at 15% from TI level. Customer contracts running well; no walkouts. Will revisit growth if geopolitical stabilizes.
Guidance
FY27 double-digit growth trajectory at consolidated level
HighQ2 delivered 33% YoY; guidance reaffirmed with T1, T2, T3 strategy focus on core and new ventures.
Higher double-digit EBIT margin improvement, cost recovery in 1-2 quarters
MediumCommodity and FX headwinds to reverse; pricing lag of 1-2 quarters acknowledged; recovery unproven.
Medical business to achieve higher double-digit teen profitability margins
MediumPost-Q3 when team in place; investment phase ongoing; amortization drag Rs 4 Cr/quarter.
Rs 350 Cr (TI) + Rs 100 Cr (Shanthi); total group Rs 600-700 Cr FY27
HighTICMPL dominant consumer (Rs 250 Cr Q3 planned); medical and CDMO incremental.
Risks the call surfaced
TICMPL execution & profitability
HighFour EV businesses underperforming; HCV 311 units Q2, 3W 2,242 units, SCV 483 units. Analyst feedback: 'not happy with any numbers.' Breakeven Q4 FY27 depends on cost absorption and price increases.
Commodity and FX headwinds
HighCell prices, commodity surge, and rupee weakness drove BOM cost increase across all businesses. Recovery timeline 1-2 quarters; market pricing power uncertain. Engineering and metal divisions margin compression evident.
Capital allocation efficiency
HighRs 600-700 Cr annual group capex with TICMPL as dominant sink. External PE partner (Rs 2,250 Cr original investment) has NOT invested further despite planned Rs 250 Cr each in Q3 and beyond. TI funding alone; leverage/cash burn risk.
Customer concentration in emerging segments
MediumMining segment is 40% of truck revenue base. Electrification adoption depends on mining sector growth, charging infrastructure, and battery economics. Fixed-route operators concentrated in select cities (Bengaluru, Delhi, Ahmedabad).
New venture profitability timeline
MediumMedical business growing 20% but profitability deferred; CDMO regulatory approval still ~1 year away. Amortization drag Rs 4 Cr/quarter; sustainable margins (double-digit teen) post-Q3, unproven.
Management
Score 6/10. Transparent on segment numbers and cost pressures; hedged on price increases and breakeven credibility. No forward-looking revenue/margin targets quantified. Defensive when pressed on TICMPL volumes. Prior guidance on double-digit growth (met: 33% delivered), EV breakeven timeline (on track Q4 FY27), and medical 20% growth (confirmed) tracking. Margin recovery timeline extended 1-2 quarters due to cost pressures; not a miss but a delay.
1 · Q3 & Q4 FY27
Cost pass-through to customers; commodity price softening expected
2 · Q4 FY27
TICMPL HCV EBITDA breakeven target
3 · Q1 FY28
TICMPL SCV and 3-wheeler breakeven; medical profitability ramp
Stock down 50% from Oct 2024 suggests market skepticism on capital efficiency.
TII Q2: consolidated PAT +39% YoY on CG Power strength; standalone profit flat
PAT +39.2% YoY · revenue +32.7% · margins expanding
₹7,330.31 Cr
+32.7% YoY
₹420.58 Cr
+39.2% YoY
5.65%
+0.3pp YoY
₹12.87
Tube Investments' consolidated (primary basis) PAT rose 39.2% YoY to ₹420.58 Cr (owners' share ₹249.07 Cr, +33.5% YoY) on revenue of ₹7,330.31 Cr, up 32.7% YoY, with net margin expanding to 5.65% from 5.38% a year ago and 4.65% last quarter. Sequentially PAT jumped 43.1% QoQ, but that mostly reflects one subsidiary's swing back to full-quarter contribution rather than underlying seasonality. No consensus estimate for this specific quarter could be sourced in a web search, so the print is graded unknown vs street.
Q2 FY-2027 vs prior quarters
The growth is almost entirely subsidiary-led. CG Power and Industrial Solutions (56.27%-held) posted revenue of ₹3,802 Cr (+30.1% YoY) and PBT of ₹559 Cr (+44.1% YoY), accounting for over half of group revenue and the bulk of the profit beat. Shanthi Gears (stake raised from 70.46% to 73.16% this quarter via a ₹77.72 Cr block deal) went the other way — revenue down 3% YoY to ₹128 Cr and PBT down 31% to ₹20 Cr. Standalone TII itself told a flatter story: revenue grew 27.9% YoY to ₹2,710.49 Cr but PAT was effectively unchanged at ₹188.16 Cr (+0.75% YoY) and PBT rose just 1.2% (₹253.16 Cr vs ₹250.44 Cr) — the Engineering segment's revenue grew 32.3% YoY while its PBIT grew only 4.2%, pointing to standalone margin compression that the consolidated print masks. This >3-point divergence between standalone (flat) and consolidated (+39%) PAT growth means the headline is a subsidiary-consolidation story, not a parent-company one.
The stock went into the print at ₹2,276, down 8% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Board approved ₹83 Cr capex for CRSS capacity expansion at Avadi (Engineering/Metal Formed Products), funded via internal accruals, targeted for completion in FY28
FY27 capex Rs350 Cr (TI standalone) + Rs100 Cr (Shanthi Gear); total group capex Rs600-700 Cr. Rs750 Cr subsidiary investment over period (Rs250 Cr done Q4, Rs250 Cr planned Q3). Medical 20% YoY growth with profitability; EBIT margin double-digit improvement; EV: one business breakeven FY27, two in FY28.
— This quarter: met
Against management's own Q1 FY27 guidance, results are mixed: Medical segment revenue of ₹63.65 Cr grew 20.3% YoY, matching the stated "20% YoY growth" target, but segment profit fell to ₹1.07 Cr from ₹2.35 Cr a year ago — the guided "with profitability" and "double-digit EBIT margin improvement" are not yet evident. The Electric Vehicles segment posted a ₹146.47 Cr loss, narrower than the ₹157.80 Cr loss a year ago but essentially flat QoQ (-147.32 Cr), with no sign yet of the "one EV business breakeven in FY27" management flagged. On capital allocation, TII invested an additional ₹250 Cr into TI Clean Mobility's Series C CCPS this quarter — a quarter earlier than the ₹250 Cr "planned Q3" tranche cited in prior guidance — and the Board approved a fresh ₹83 Cr capex for Cold Rolled Steel Strips capacity at Avadi, on top of the ₹600-700 Cr group capex envelope already guided; H1 consolidated cash capex of ₹878.61 Cr already runs ahead of that full-year figure. Management's own press release frames the quarter around standalone revenue growth, a steady 44% annualised ROIC and ₹167 Cr of free cash flow, but is silent on the near-flat standalone PBT/PAT — the numbers show the margin pressure its framing doesn't call out. Separately, the company disclosed a ₹39 lakh fine for environmental non-compliance on November 2, immaterial to the P&L.
W1
EV segment loss (₹146.47 Cr this quarter) narrowing toward the 'one business breakeven in FY27' management guided on the Q1 call
W2
Medical segment profitability (₹1.07 Cr this quarter, down from ₹2.35 Cr YoY) catching up to its 20%+ revenue growth, per the guided double-digit EBIT margin improvement
W3
FY27 capex pace against the guided ₹600-700 Cr group envelope, given H1 consolidated cash capex already at ₹878.61 Cr plus the new ₹83 Cr Avadi approval
Clean digital filing, columns unambiguous. Consol PBT (643.82) = totalIncome-totalExpenses (643.04) + share of JV/associate profit (0.78); PAT ties exactly to PBT-tax on both statements. No exceptional items in current or year-ago quarter (the FY26 New Labour Code charge of ₹22.75 Cr standalone/₹67.96 Cr consol sat in the full year, not in Q2FY26), so no adjusted-vs-reported PAT split is needed. Consol PAT split: owners ₹249.07 Cr, non-controlling interest ₹171.51 Cr (mainly CG Power, TICMPL minorities).
Growth That Doesn't Convince: TICMPL's Cost Trap and the Street's Exit
TI delivered 33% revenue growth and 39% profit expansion, but margin compression from commodity headwinds and TICMPL volumes running 20–30% below management's own comfort level are stretching credibility. The street is voting with its feet — FII ownership down, stock down 54% from its all-time high.
₹7,330 Cr
+33% YoY
₹421 Cr
+39% YoY
5.7%
Down from prior year; commodity drag
311 units
Analyst: 'should be higher'
TI's headline numbers tell a boom story—33% revenue growth, 39% profit expansion—but the quarter's honest read is messier. Consolidated PAT of ₹421 Cr masks a margin squeeze that management is banking on commodity normalization to heal. Meanwhile, the company's high-stakes EV venture, TICMPL, is running 20–30% behind volumes that management itself admits should be higher, and costs are 75% above the baseline needed for profitability. The market has already judged: stock down 54% from its all-time high of ₹4,810.8, FII ownership down 3.97pp over five quarters, and analysts branding it a 'Hold' at best.
What held up on the call
Double-digit growth trajectory at consolidated level
SupportedDelivered 32.7% YoY revenue, 39.2% PAT
Medical business growing 20% YoY with profitability scaling
SupportedConfirmed on call; exact Q2 contribution not separated
Cost headwinds will be recovered in 1–2 quarters
OverstatedQ2 OPM 10.0% vs. prior guidance; timeline unproven
TICMPL volumes scaling across four businesses
ContradictedTruck 311, 3W 2,242, SCV 483, Tractor 50 units; analyst: 'not happy with any numbers'
TICMPL HCV will be EBITDA breakeven Q4 FY27
UnverifiedTarget stated; not yet achieved; costs 75% above run-rate
The margin squeeze
Here's the real story of Q2: commodity surge, cell price spikes, and rupee weakness hit the business harder and faster than the company's pricing power could recover. Engineering and Metal Formed Products divisions both saw PBIT margins compress despite volume growth. The response? Management is betting on a 1–2 quarter lag to pass through cost increases to OEMs and customers. That timing is explicitly unproven—management itself said 'the market may not be ready' for price hikes. The alternative levers they cited (BOM optimization, deal realization improvements) are incremental, not game-changing.
TICMPL: the capital trap
TICMPL is TI's ₹600–700 Cr annual capex sink, a push into electric trucks, 3-wheelers, SCVs, and tractors with grand ambitions (₹1 Bn revenue by 2030). The problem: execution is lagging and external validation is gone. The PE partner who wrote the original ₹2,250 Cr cheque has not invested any further capital after the initial stake. TI is now funding the venture entirely on its own cash, and the volumes tell you why external investors are skeptical. Q2 TICMPL volumes: Truck 311 units, 3W 2,242 units, SCV 483 units, Tractor 50 units. These are sub-scale for a business burning ₹250 Cr+ per quarter in capex. Analyst Vipulkumar Shah was blunt during Q&A: 'I am not happy with any of the four numbers. All four numbers should be higher.' Management acknowledged the miss but offered no revised targets—instead retreating to 'market share matters, we have 25–26% in two segments.'
I am not happy with any of the four numbers. In my view, all four numbers should be higher.
Breakeven is promised for Q4 FY27—three quarters away—but costs are running ₹75 Cr above baseline, and management's confidence hinges on price increases ('one to two quarters to settle prices with customers and OEMs') that the market 'may not be ready' to absorb. This is not a credible path to profitability; it's a hope.
What changed on this call
Cost pressure timeline extended 1–2 quarters (vs. immediate recovery prior call implied); no change to FY27 guidance
TICMPL capex Q3 reaffirmed at ₹250 Cr; total group capex Rs 600–700 Cr FY27 unchanged
EV breakeven timeline reaffirmed: HCV Q4 FY27, two others Q4 FY28; no slip
Medical business 20% growth and double-digit teen profitability target post-Q3 reaffirmed
Analyst pushback on TICMPL volumes (Shah, Desai, Gnanasundaram) was harder than prior quarter; management acknowledged but didn't preemptively disclose
How the street is positioned
Price & valuation: Stock at ₹2,209.5 (as of 2026-11-09) is down 54.07% from its all-time high of ₹4,810.8. It trades above its 20-day SMA (₹2,167.89) but well below its 50-day (₹2,393.42) and 200-day (₹2,694.15) averages—a downtrend confirmed. RSI at 46.5 shows no momentum overshoot either way; the stock is drifting. Volume trend is normal, not panic-selling, but the persistent drawdown is the market's own verdict: the growth story is not convincing at current capital intensity. Ownership flows: FII shareholding has contracted from 26.31% in Q1 FY26 to 22.34% in Q1 FY27—a drop of 3.97pp over five quarters. DIIs are flat (slightly down 0.73pp QoQ). Promoter stake stable at ~44%. The FII exit is the real signal: large institutions have de-risked TI, unconvinced by the TICMPL bet and the margin pressure. That vote of non-confidence matches the sell-off.
Consolidated revenue 32.7% YoY with core segments healthy; secular tailwinds in EV and medical intact
Free cash flow ₹167 Cr in Q2; FCF-to-PAT conversion at target 85%; debt/equity stable
Medical 20% growth and CDMO path to regulatory approval (next CY) are credible long-term bets
Net margin 5.7% reflects commodity surge and FX pressure, not operational miss; recovery lag is real
TICMPL volumes 20–30% below management's own comfort; external capital withdrew; breakeven unproven
Cost pass-through timeline 1–2 quarters hinges on market readiness; management said 'market may not be ready'
FII ownership down 3.97pp in five quarters; stock down 54% from ATH despite 39% PAT growth
TICMPL execution & profitability gap
HighFour EV businesses underperforming; analyst directly stated 'volumes should be higher.' Breakeven Q4 FY27 depends on unproven price increases and cost absorption. If profitability slips into Q1 FY28, capital is trapped and ROI credibility collapses.
Commodity and FX headwinds; cost pass-through lag
HighQ2 margin compression is real; recovery timeline 1–2 quarters is management's hope, not confirmed. If commodity prices persist or rupee stays weak, margin recovery is delayed further, eating into FY27 and FY28 earnings.
External capital withdrawal from TICMPL
HighPE partner has not invested further after initial ₹2,250 Cr stake. TI now fully funding Rs 600–700 Cr annual group capex on its own cash. If TICMPL struggles, TI absorbs 100% of capex drag with no partner to share upside.
Credibility strained; analysts pressing hard
MediumQ&A was unusually adversarial (Shah, Desai, Gnanasundaram pushing on volumes, costs, capital allocation). If next quarter repeats miss, analyst sentiment will shift from cautious to bearish, triggering further selling.
Customer concentration & pricing power
MediumMining is 40% of TICMPL truck revenue; fixed-route operators concentrated in Bengaluru, Delhi, Ahmedabad. If mining demand cools or EV adoption stalls in concentrated use cases, volumes will be under-estimated, not just under-managed.
Medical and CDMO profitability deferred
MediumAmortization drag ₹4 Cr/quarter; medical sustainable margins still unproven ('higher double-digit teen' post-Q3); CDMO approval ~1 year out. Near-term NPM will remain pressured until these scale.
1 · Cost pass-through evidence—pricing power
Did Q3 see meaningful price increases to OEMs and customers? Or did the 'market not ready' comment prove prescient? Margin trajectory is the bellwether.
2 · TICMPL volume acceleration
Q3 must show volumes materially higher than Q2—not just QoQ but a signal that the business can scale. Analyst bar is high after Q2 feedback. Truck and 3W units are the metrics to watch.
3 · TICMPL HCV breakeven Q4 timeline credibility
Q3 will show cost trajectory and customer adoption. If costs are still 50%+ above baseline or volume growth stalls, Q4 breakeven promise loses credibility and the stock re-rates lower.
4 · FII re-entry or continued exit
Watch Q3-Q4 F&O FII flows and bulk-block trades. If FII stays exiting, it signals street skepticism persists despite fundamental recovery.
TI's Q2 is a tale of two companies: the core engineering and metal business is executing well, growing 32%+ with stable returns. TICMPL and the margin pressure are the fracture lines. Growth without margin recovery at a company with high capex intensity is not a turnaround story; it's a capital trap in slow motion. The street has priced that skepticism in—stock down 54% from highs, FII exiting, analysts rating it Hold.
The quarter does not change the debate. Strong headline growth masks execution risk, and near-term margin recovery is uncertain. TI is not a sell, but it's a hold until TICMPL volumes and profitability credibly move higher and commodities stabilize. The number to track: Q3 TICMPL volumes and gross margins. That is the make-or-break metric for the next 12 months.
Q2 FY27: Revenue Momentum on Track, Margin Recovery the Verdict
TII faces the Street's core question: can it hold 15%+ revenue growth while reclaiming margin pressure? Steel cost pass-through and Clean Mobility's ramp will define the read.
The Setup
Tube Investments enters Q2 FY27 on a paradox: revenue trajectory is healthy and the Street believes in the margin thesis, yet the stock is down 55% from ATH. The quarter ended 30 September 2026 will test whether management's steel cost pass-through story is holding and whether its full-year guidance is on track. The consensus is cautiously bullish — median analyst target stands at ₹3,402 vs. current price of ₹2,120 — but execution risk on margin recovery is the debate.
~₹6,300–6,450 Cr
Implies 15–18% YoY growth (Q1 was +17.1%). Guidance trajectory on-plan if realised.
~₹300–320 Cr
Q1 declined 3% to ₹294 Cr despite revenue growth. Recovery swing depends on margin pass-through and mix.
~13–14%
Core watch: Q1 saw margin compression from cost inflation. Q2 should show early recovery if steel/raw-material cost pass-through is in effect.
Likely widening
Fresh ₹250 Cr investment (Sep 2026) means subsidiary burn continues; group consolidation will mask some PAT lift.
A strong quarter would show: revenue in-line or above ₹6,400 Cr, standalone EBITDA margin recovery to 13%+ (vs. ~12.5% in Q1), and any early sign of Clean Mobility gross margin traction or slowing cash burn. A weak quarter would flag: revenue growth slower than 12%, EBITDA margin still compressed, and elevated commentary on delayed cost recovery or a pull-back in engineering/mobility order book. The Street will parse management's updated FY27 guidance and commentary on when cost inflation will fully unwind from the income statement.
On Track?
TII's full-year FY27 guidance (unverified vs. actuals) and the run-rate from Q1 point to mid-to-high teens revenue growth sustainable across the year. The margin outlook is the uncertainty. Management has signalled that raw-material cost pressures (steel, aluminium, non-ferrous) are being recovered with a lag, and Q2 should show incremental progress on that front. If Q2 EBITDA margin sits below Q1 levels, the Street will reprrice the timing of margin recovery, potentially capping the stock's re-rating.
What the Street Says
Since Last Quarter
1 · ESG ratings (Aug 14 & Oct 16)
CRISIL ESG 65 (Core ESG 70); NSE Sustainability rated TII 69. Routine credit-ratings improvement; no material operational signal.
2 · Shanthi Gears stake increase (Aug 21)
TII acquired additional 2.69% equity in Shanthi Gears for ₹77.49 Cr via block deal. Subsidiary consolidation move; not operationally material to Q2 earnings but signals confidence in portfolio.
3 · Clean Mobility ₹250 Cr investment (Sep 29)
TII committed fresh capital to TICMPL for EV ramp. Reflects long-term bets but increases near-term cash burn. Expect widened losses in Clean Mobility line through FY27.
4 · Trading window closure (Sep 28)
Routine; standard compliance for Q2 results.
5 · Board meeting scheduled (Oct 26)
Board to meet on Nov 5, 2026 to approve Q2 FY27 (unaudited) results. Confirms result date.
On Result Day: Watch For
1 · Standalone EBITDA margin trajectory
Has inflation headwind started to reverse (i.e., margin vs. Q1)? The Street will back-calc gross margin from quarterly P&L. Any margin accretion is +ve; stagnation re-prices cost-pass-through timing.
2 · Clean Mobility cash burn & opex guidance
How fast is the EV subsid burning? Management commentary on when it reaches cash-flow breakeven will reshape the investment thesis. Larger subsidy burn compresses group PAT, even with core margin recovery.
3 · FY27 full-year guidance reaffirm/revise
Is mid-to-high teens revenue growth on-plan? Any change to PAT guidance will signal management's confidence in cost recovery and Clean Mobility trajectory.
Tube Investments enters Q2 with strong revenue momentum but margin pressure still the headline risk. The Street is constructive (Buy, ₹3,402 target) because it believes cost inflation is transient and will unwind in H2 FY27. Q2 earnings will show whether that thesis is valid — specifically, whether standalone EBITDA margin is recovering and whether Clean Mobility burn is as managed as TII claims. Revenue should follow the on-plan path. The real test is the margin re-rate and FY27 PAT credibility post-Clean Mobility ramp.
The stock's 55% drawdown from ATH reflects not fundamental deterioration but valuation reset and cost-recovery timing uncertainty. A strong Q2 margin print and stable FY27 guidance could re-ignite re-rating; a miss will likely extend the consolidation.